和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

未开盘 07-23 16:08:06

10.660

+0.120

+1.14%

最高10.880	最低10.460	成交量65.20万
今开10.650	昨收10.540	日振幅3.98%
总市值76.54亿	流通市值76.54亿	总股本7.18亿
成交额695.00万	换手率0.09%	流通股本7.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":10.66,"timestamp":1784794086004,"preClose":10.54,"halted":0,"volume":652000,"delay":0,"changeRate":0.011385199240986812,"floatShares":718000000,"shares":718000000,"eps":0.088442,"marketStatus":"未开盘","change":0.12,"latestTime":"07-23 16:08:06","open":10.65,"high":10.88,"low":10.46,"amount":6950047,"amplitude":0.039848,"askPrice":10.66,"askSize":2000,"bidPrice":10.65,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":0.085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":0,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":10.54,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.5733479050667193,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2651357064","title":"港股异动 | 和誉-B(02256)涨超5% 和誉医药宣布口服小分子pan-KRAS抑制剂ABSK211的IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651357064","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651357064?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:15","pubTimestamp":1784085335,"startTime":"0","endTime":"0","summary":"本集团无法保证ABSK211最终将成功获批上市。ABSK211是和誉医药自主研发的一款新型口服、高效力、高选择性小分子pan-KRAS抑制剂，旨在覆盖多种KRAS基因改变，包括常见KRAS突变亚型及特定扩增状态。临床前研究结果显示，ABSK211在单药及联合治疗场景中均展现出积极的抗肿瘤活性及良好的选择性，有望为携带KRAS基因改变的实体瘤患者提供新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU2476274720.SGD","BK4588","BK4585","02256","IE00B5MMRT66.SGD","159938","LU2778985437.USD","LU2476274308.USD","BK1515","LU2488822045.USD","IE00BPRC5H50.USD","KCAI","IND","VXUS","IE00B543WZ88.USD","09939","LABU","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154649038","title":"和誉-B于7月13日回购2.00万股，合计耗资约22.18万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154649038","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154649038?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:06","pubTimestamp":1783937187,"startTime":"0","endTime":"0","summary":"和誉-B于2026年7月13日公告， 当日于香港联交所场内回购2.00万股普通股，占该交易日前已发行股份约0.00279%。每股回购价格介乎11.02港元至11.17港元，合计耗资约22.18万港元。回购完成后，公司已发行股份由717,921,350股降至717,901,350股，而库藏股数量则由8,284,000股增至8,304,000股，公司股本总数仍为726,205,350股。根据公告，和誉-B先前于2026年5月20日通过购回授权，允许最高可回购71,646,135股，截至目前已累计回购560,000股，占授权通过时已发行股份的约0.07816%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B于7月13日回购2.00万股，合计耗资约22.18万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651118926","title":"和誉-B(02256)7月13日耗资22.175万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651118926","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651118926?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:03","pubTimestamp":1783937022,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)公布，2026年7月13日耗资22.175万港元回购2万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","02256","LU2488822045.USD","LU2778985437.USD","LU2476274308.USD","LU2476274720.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194467861","title":"和誉-B口服小分子泛KRAS抑制剂ABSK211获美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1194467861","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194467861?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:34","pubTimestamp":1783906470,"startTime":"0","endTime":"0","summary":"7月13日（路透社）—— 和誉-B（股票代码：2256.HK）宣布，其口服小分子泛KRAS抑制剂ABSK211已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。\n此次获批意味着该候选药物已获准在美国开展临床试验，标志着公司在针对KRAS靶点的创新药物研发领域取得了重要进展。KRAS是癌症中常见的突变基因之一，长期以来被视为“不可成药”靶点。ABSK211作为一款泛KRAS抑制剂，旨在靶向多种KRAS突变亚型，为相关癌症患者提供潜在的治疗选择。\n公司表示，将积极推进ABSK211的后续临床开发工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU2778985437.USD","02256","IE00B543WZ88.USD","BK1161","IE00B5MMRT66.SGD","LU2488822045.USD","LU2476274720.SGD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651495161","title":"和誉-B(02256.HK)：和誉医药宣布口服小分子pan-KRAS抑制剂ABSK211新药临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651495161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651495161?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:09","pubTimestamp":1783901347,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","BK1515","BK1161","LU2476274720.SGD","02256","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2476274308.USD","LU2778985437.USD","BK1574","09939","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163862819","title":"和誉-B(02256)披露：口服小分子pan-KRAS抑制剂ABSK211获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1163862819","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163862819?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:05","pubTimestamp":1783901135,"startTime":"0","endTime":"0","summary":"2026年7月13日，和誉开曼有限责任公司公告，其全资子公司上海和誉生物医药科技有限公司收到美国食品药品监督管理局关于口服、高效力、高选择性小分子pan-KRAS抑制剂ABSK211的新药临床试验批准，用于治疗携带KRAS基因改变的晚期实体瘤患者。此次获批试验为一项开放性Ⅰ期临床研究，将评估ABSK211的安全性、耐受性、有效性及药代动力学特征。此外，ABSK211在联合治疗中亦表现出潜力。ABSK211已分别获得中国和美国IND批准，正在开展全球临床开发。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168887","title":"和誉-B获Allianz SE增持59.9万股 每股作价约11.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168887","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650168887?lang=zh_cn&edition=full","pubTime":"2026-07-12 15:31","pubTimestamp":1783841460,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，7月7日，Allianz SE增持和誉-B（02256）59.9万股，每股作价11.4113港元，总金额约为683.54万港元。增持后最新持股数目为5114.5万股，最新持股比例为7.06%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-12/doc-inihpucx7809532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2476274720.SGD","ALIZF","LU2488822045.USD","BK4117","IE00BPRC5H50.USD","02256","LU2778985437.USD","ALIZY","LU2476274308.USD","IE00B543WZ88.USD","BK1161","EWH","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650182437","title":"Allianz SE增持和誉-B(02256)59.9万股 每股作价约11.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650182437","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650182437?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:16","pubTimestamp":1783682187,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月7日，Allianz SE增持和誉-B(02256)59.9万股，每股作价11.4113港元，总金额约为683.54万港元。增持后最新持股数目为5114.5万股，最新持股比例为7.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","02256","EWH","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2476274308.USD","BK1161","LU2488822045.USD","BK4117","IE00B5MMRT66.SGD","LU2778985437.USD","ALIZY","ALIZF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188643917","title":"和誉-B：7月10日回购3万股股份，耗资约32.45万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188643917","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188643917?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:46","pubTimestamp":1783676783,"startTime":"0","endTime":"0","summary":"和誉-B于2026年7月10日回购3万股股份，占当日已发行股本约0.00418%，每股回购价介乎港币10.69元至11.03元，涉资约32.45万港元。公告显示，本次回购股份将持作库藏股。\\n\\n回购完成后，公司已发行股份数为717,921,350股，库藏股数量增至8,284,000股，总股本为726,205,350股。公司于2026年5月20日通过了购回授权，最多可回购71,646,135股，截至目前已累计回购540,000股，占购回授权通过时已发行股本的约0.07537%。\\n\\n公司强调，本次回购股份活动已遵守香港联交所上市规则及相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B：7月10日回购3万股股份，耗资约32.45万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650189698","title":"和誉-B(02256)7月10日斥资约32.45万港元回购3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650189698","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650189698?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:45","pubTimestamp":1783676702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年7月10日该公司斥资约32.45万港元回购3万股，回购价格为每股10.69至11.03港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","IE00B543WZ88.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","IE00BPRC5H50.USD","LU2488822045.USD","BK1161","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169575366","title":"和誉-B：7月9日回购2万股股份，涉资约22.76万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169575366","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169575366?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:26","pubTimestamp":1783596400,"startTime":"0","endTime":"0","summary":"2026年7月9日，和誉-B发布翌日披露报表，公告当日于香港联交所回购2万股普通股，占该公司当时已发行股本的约0.00279%。本次回购每股最高价格11.68港元、最低价格11.18港元，合计付出价款约22.76万港元。经回购后，和誉-B的已发行股本减少至717,951,350股，库存股份增至8,254,000股，公司总已发行股本维持在726,205,350股。公告显示，和誉-B于2026年5月20日通过购回授权，可购回股份总数为71,646,135股，至今已累计回购510,000股，占购回授权通过当日已发行股本的约0.07118%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B：7月9日回购2万股股份，涉资约22.76万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165264863","title":"和誉-B7月8日回购2万股，耗资约23.51万港元并合计发行200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1165264863","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165264863?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:26","pubTimestamp":1783509999,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年7月8日发布翌日披露报表，披露近期股份回购及已发行股本变动情况。公告显示，2026年7月3日，公司根据股份计划向非董事级参与人合计新增发行2,000,000股普通股，分别为275,000股、918,708股、234,175股及572,117股，占上述增发前已发行股本约0.03841%、0.12831%、0.03271%及0.07991%。本次回购股份将作库存股份持有。此次股份发行及回购完成后，截至2026年7月8日，公司已发行股份总数由2026年6月30日的715,991,350股增至717,971,350股，库存股份数为8,234,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B7月8日回购2万股，耗资约23.51万港元并合计发行200万股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998280","title":"和誉-B(02256)7月8日斥资23.51万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998280","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649998280?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:23","pubTimestamp":1783509814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年7月8日该公司斥资23.51万港元回购2万股，回购价格为每股11.74-11.76港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","02256","LU2488822045.USD","BK1161","LU2476274720.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2778985437.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649961183","title":"大行评级丨瑞银：下调和誉目标价至17.5港元，重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2649961183","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649961183?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:50","pubTimestamp":1783500650,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2488822045.USD","BK1161","LU2476274308.USD","02256","LU2778985437.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132082387","title":"和誉-B更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1132082387","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132082387?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:36","pubTimestamp":1782981364,"startTime":"0","endTime":"0","summary":"2026年7月2日，和誉开曼有限责任公司披露截至2026年6月30日的股份变动月报表。公告显示，公司注册股本与已发行股份总数本月保持不变，注册股本仍为5,000,000,000股普通股，总额USD 50,000。同时，公司确认依然符合香港联交所规定的最低公众持股量要求。整体而言，本月至6月底，股本总数保持724,205,350股。该月报表由联席公司秘书张菡兮签署，公司声明将继续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176633224","title":"和誉制药与阿斯利康达成战略合作，共同开展首创新药口服PD-L1抑制剂Lumipodlin联合泰瑞沙®治疗非小细胞肺癌的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1176633224","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176633224?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:02","pubTimestamp":1782954174,"startTime":"0","endTime":"0","summary":"和誉制药与阿斯利康宣布达成一项战略合作，将共同推进一项临床研究。该试验旨在评估其首创新药口服PD-L1抑制剂Lumipodlin（研发代号：Absk043）与阿斯利康已上市药物泰瑞沙®联合疗法，在非小细胞肺癌患者中的疗效与安全性。\n此次合作标志着在肿瘤免疫治疗领域，一种创新口服疗法与成熟靶向药物的强强联合，有望为非小细胞肺癌患者带来新的治疗选择。双方将整合各自的研发资源与专长，加速这一潜在组合疗法的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","BK1161","IE00B5MMRT66.SGD","LU2488822045.USD","02256","IE00BPRC5H50.USD","LU2476274720.SGD","LU2476274308.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648220025?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU1169589451.USD","LU1267930573.SGD","BK4588","BK4585","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU2236285917.USD","LU0320765992.SGD","LU2237443622.USD","02256","IE00B3T34201.USD","LU0432979614.USD","LU0029864427.USD","LU0109394709.USD","LU2237443465.HKD","LU0058720904.USD","BK4007","LU1829250122.USD","LU2089984988.USD","LU2468319806.SGD","LU2476274308.USD","AZN","LU2237443382.USD","IE00B543WZ88.USD","LU2237443895.HKD","IE00BPRC5H50.USD","BK1161","LU2476274720.SGD","LU2417539215.USD","PD","LU2462157665.USD","LU0128525929.USD","LU2778985437.USD","LU0889565916.HKD","LU1169590202.USD","AZNH","LU2456880835.USD","LU2237443978.SGD","LU2488822045.USD","BK4023","LU2237443549.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109487916","title":"和誉-B与阿斯利康就Lumipodlin在非小细胞肺癌的临床试验达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1109487916","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109487916?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:03","pubTimestamp":1782950591,"startTime":"0","endTime":"0","summary":"和誉-B与阿斯利康制药宣布，双方已就Lumipodlin在非小细胞肺癌领域的临床试验达成一项战略合作。此次合作旨在加速该候选药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0960981461.USD","LU1104425308.USD","LU0047473722.EUR","LU2023251221.USD","LU0738911758.USD","IE0002141913.USD","LU1355424745.HKD","LU2108987350.USD","LU0496365809.HKD","LU1989772923.USD","LU0128525689.USD","LU2488822045.USD","LU1003077747.HKD","LU0857590862.USD","LU0310799852.SGD","LU0310800965.SGD","03165","IE00B2B36J28.USD","LU0964806797.USD","LU2089283258.USD","LU1078025761.USD","LU0545039389.USD","LU0823416689.USD","LU2125909593.SGD","LU0203345920.USD","LU1153585028.USD","LU0557290698.USD","LU0432979614.USD","LU2237443549.SGD","IE00B5MMRT66.SGD","LU0211326839.USD","LU0827474353.SGD","LU1496350171.SGD","LU0859254822.USD","LU0823399737.USD","LU2237443382.USD","LU0882574055.USD","LU2468319806.SGD","LU0553294199.USD","LU1119994496.HKD","LU2091194634.USD","LU2539964713.USD","LU0077335932.USD","LU2293690249.USD","LU0499090636.EUR","LU0114720955.EUR","LU0640478417.SGD","LU2476274308.USD","LU0963555726.SGD","LU2237443465.HKD","LU1019634622.SGD","LU2476274720.SGD","LU1267930490.SGD","LU1267930227.SGD","LU0757432116.USD","LU1487256676.USD","LU1481599808.USD","LU1019632923.USD","LU2114397693.USD","LU2125909247.SGD","LU2324357040.USD","LU1267930573.SGD","LU1267930813.SGD","LU0158827948.USD","AZN.UK","IE00B4R5TH58.HKD","LU1301847155.USD","LU0266013472.USD","LU0171276677.USD","IE00BPRC5H50.USD","LU0972486137.USD","LU0997586515.USD","LU1064927863.SGD","LU1923622614.USD","LU1989771016.USD","LU0708994859.HKD","LU0047473722.SGD","LU0887340254.USD","LU0949170426.SGD","IE00B3T34201.USD","LU1261432733.SGD","LU2237443622.USD","LU1880407215.USD","LU0997586432.USD","LU0784383803.USD","LU1880407132.USD","02256","LU1153584641.USD","SG9999001176.SGD","LU1814569148.SGD","LU0575583348.USD","LU1983299246.USD","LU0058720904.USD","LU0976567544.SGD","LU0211326755.USD","LU0526926950.USD","LU2089284900.SGD","LU2112291526.USD","LU0289739699.SGD","LU0784385840.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU2133065610.SGD","LU1196032939.SGD","LU1084165304.USD","LU2237443978.SGD","LU2293690082.USD","LU1291159041.SGD","IE00BKPKM643.USD","LU0390134368.USD","LU2778985437.USD","LU1323610961.USD","IE0009355771.USD","LU1989772840.SGD","LU0784384876.USD","LU0920783379.SGD","LU0957799991.USD","BK1161","LU2355687059.USD","LU1170363599.USD","LU0011850046.USD","LU1061106388.HKD","BK5011","LU0920840948.USD","IE00B543WZ88.USD","LU1496350502.SGD","LU0203347892.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU1015430645.USD","SG9999013999.USD","LU0310800379.SGD","LU0029864427.USD","LU2433249047.HKD","LU1273509221.SGD","LU1829250122.USD","LU0128525929.USD","LU0969580561.USD","LU2279689827.SGD","LU0792757196.USD","LU0661504455.SGD","LU0211327993.USD","LU1051770623.HKD","IE0034235188.USD","LU1481600234.SGD","LU1003076772.USD","LU0052756011.USD","LU2237443895.HKD","LU1023059063.AUD","SG9999001176.USD","LU0784385170.HKD","LU0171293334.USD","LU0211328371.USD","LU0949170772.SGD","LU0345777147.USD","LU1046234339.USD","LU0889565080.SGD","SGXZ57979304.SGD","LU0345777659.USD","LU2357627491.SGD","LU0889566641.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168804061","title":"和誉-B回购2.00万股股份，总额约19.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168804061","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168804061?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:32","pubTimestamp":1782729154,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年6月29日公布翌日披露报表，披露当日于香港联交所场内回购2.00万股股份，占当日现有已发行股份约0.00279%。本次回购价格区间为每股9.55港元至9.76港元，总耗资约19.40万港元。公司购回授权决议于2026年5月20日通过，可购回股份总数为71,646,135股。公司同时确认，此次股份回购交易已获得董事会正式授权并遵照香港联交所相关上市规则和法律法规完成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B回购2.00万股股份，总额约19.40万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647981373","title":"和誉-B(02256.HK)6月29日斥资约19.4万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647981373","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647981373?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:30","pubTimestamp":1782729008,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2476274720.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","02256","BK1161","LU2476274308.USD","LU2488822045.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.0422},{"period":"1month","weight":0.1844},{"period":"3month","weight":-0.2162},{"period":"6month","weight":-0.2314},{"period":"1year","weight":0.0618},{"period":"ytd","weight":-0.1806}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.0803},{"period":"3month","weight":-0.0295},{"period":"6month","weight":-0.0575},{"period":"1year","weight":-0.0128},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.122249},{"month":2,"riseRate":0.8,"avgChangeRate":0.040621},{"month":3,"riseRate":0.4,"avgChangeRate":0.033777},{"month":4,"riseRate":0.4,"avgChangeRate":0.005698},{"month":5,"riseRate":0.2,"avgChangeRate":-0.025571},{"month":6,"riseRate":0.6,"avgChangeRate":0.025986},{"month":7,"riseRate":0.6,"avgChangeRate":0.036144},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}